secwatch.observer — SEC 8-K summary ====================================== Issuer: Scribe Therapeutics, Inc. (SCTX) CIK: 0001853921 Form: 8-K Filed at: 2026-09-02T20:08:19+00:00 Accession: 0001193125-26-380184 Event type: earnings Sentiment: positive Materiality: 0.75 Item codes: 2.02, 9.01 LLM model: deepseek-v4-flash:cloud@v2 Scribe Therapeutics Q2 2026 net loss $6.5M; cash $43M plus $140.6M IPO proceeds fund to H1 2029 -------------------------------------------------------------------------------- - Q2 net loss $6.5M ($2.62/share) vs $9.9M ($4.08) YoY; collaboration revenue $1.9M vs $4.9M. - Cash & marketable securities $43.0M at 6/30/26; July IPO + Sanofi placement raised $155.5M gross, $140.6M net. - Initiated first-in-human Phase 1 of STX-1150 (PCSK9 epigenetic silencing); NHP data showed up to 68% LDL-C reduction. - Awarded ~$25.7M CIRM grants: $12.7M for STX-1200 (Lp(a)), $13.0M for STX-1400 (triglycerides). - R&D expenses fell to $8.8M from $13.9M; management expects run-rate funding into H1 2029. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/0001193125-26-380184-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/sctx-20260902.htm HTML page: https://secwatch.observer/filing/0001193125-26-380184 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer